Cargando…
Antitumour imidazotetrazines: past, present… and future?
It is 40 years since the publication of the patent that announced the imidazotetrazines temozolomide and mitozolomide to the world and 30 since the discovery that they function as prodrugs of alkyldiazonium reactive intermediates. Temozolomide combined with radiation is established as the first-line...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
RSC
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549241/ https://www.ncbi.nlm.nih.gov/pubmed/37799580 http://dx.doi.org/10.1039/d3cb00076a |
| _version_ | 1785115380722696192 |
|---|---|
| author | Stevens, Malcolm F. G. Wheelhouse, Richard T. |
| author_facet | Stevens, Malcolm F. G. Wheelhouse, Richard T. |
| author_sort | Stevens, Malcolm F. G. |
| collection | PubMed |
| description | It is 40 years since the publication of the patent that announced the imidazotetrazines temozolomide and mitozolomide to the world and 30 since the discovery that they function as prodrugs of alkyldiazonium reactive intermediates. Temozolomide combined with radiation is established as the first-line treatment for glioma but despite the attentions of the inventors and others, further examples of this intriguing ring system have yet to enter the clinic. |
| format | Online Article Text |
| id | pubmed-10549241 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | RSC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105492412023-10-05 Antitumour imidazotetrazines: past, present… and future? Stevens, Malcolm F. G. Wheelhouse, Richard T. RSC Chem Biol Chemistry It is 40 years since the publication of the patent that announced the imidazotetrazines temozolomide and mitozolomide to the world and 30 since the discovery that they function as prodrugs of alkyldiazonium reactive intermediates. Temozolomide combined with radiation is established as the first-line treatment for glioma but despite the attentions of the inventors and others, further examples of this intriguing ring system have yet to enter the clinic. RSC 2023-08-29 /pmc/articles/PMC10549241/ /pubmed/37799580 http://dx.doi.org/10.1039/d3cb00076a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
| spellingShingle | Chemistry Stevens, Malcolm F. G. Wheelhouse, Richard T. Antitumour imidazotetrazines: past, present… and future? |
| title | Antitumour imidazotetrazines: past, present… and future? |
| title_full | Antitumour imidazotetrazines: past, present… and future? |
| title_fullStr | Antitumour imidazotetrazines: past, present… and future? |
| title_full_unstemmed | Antitumour imidazotetrazines: past, present… and future? |
| title_short | Antitumour imidazotetrazines: past, present… and future? |
| title_sort | antitumour imidazotetrazines: past, present… and future? |
| topic | Chemistry |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549241/ https://www.ncbi.nlm.nih.gov/pubmed/37799580 http://dx.doi.org/10.1039/d3cb00076a |
| work_keys_str_mv | AT stevensmalcolmfg antitumourimidazotetrazinespastpresentandfuture AT wheelhouserichardt antitumourimidazotetrazinespastpresentandfuture |